Publications

Armstrong et al. evaluated the long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis over a three-year period. The study found that exposure-adjusted incidence rates of AEs remained stable or declined over time, with no new safety signals emerging. Clinical response rates, including PASI75/90, were maintained, supporting the drug’s long-term efficacy.

The analysis of the POETYK PSO-1 and POETYK PSO-2 clinical trials showed that deucravacitinib 6mg QD displayed efficacy as early as 1 week, and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.

Week 16 coprimary endpoints of PASI 75 response and sPGA score improved in the majority of patients and was overall maintained through week 52. Deucravacitinib therapy was also associated with a low AE rate. This study presented results from the POETYK PSO-4 trial on the safety and efficacy of deucravacitinib 6mg QD in Japanese patients with psoriasis.

Researchers reported the safety and efficacy of deucravacitinib over 2 years in patients with chronic plaque PsO. The most frequently reported AEs were nasopharyngitis, URTI, and COVID-19.

Deucravacitinib has shown efficacy in the treatment of both skin and joint disease. As a result, researchers sought to compare the efficacy and safety of deucravacitinib versus placebo and apremilast in adults with moderate to severe plaque PsO.